LLY

982

-0.81%↓

JNJ

222.64

-1.1%↓

ABBV

205.57

-0.13%↓

UNH

367.51

+0.93%↑

AZN

182.62

-0.63%↓

LLY

982

-0.81%↓

JNJ

222.64

-1.1%↓

ABBV

205.57

-0.13%↓

UNH

367.51

+0.93%↑

AZN

182.62

-0.63%↓

LLY

982

-0.81%↓

JNJ

222.64

-1.1%↓

ABBV

205.57

-0.13%↓

UNH

367.51

+0.93%↑

AZN

182.62

-0.63%↓

LLY

982

-0.81%↓

JNJ

222.64

-1.1%↓

ABBV

205.57

-0.13%↓

UNH

367.51

+0.93%↑

AZN

182.62

-0.63%↓

LLY

982

-0.81%↓

JNJ

222.64

-1.1%↓

ABBV

205.57

-0.13%↓

UNH

367.51

+0.93%↑

AZN

182.62

-0.63%↓

Начало・Списък с акции・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Затворен

СекторЗдравеопазване

12.6 -4.83

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.6

Максимум

13.53

Ключови измерители
By Trading Economics
Приходи	227M
Продажби	139M
P/E Средно за сектора	4.989 49.8
Марж на печалбата	163.843
Служители	1,796
EBITDA	1.3M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+48.92% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.3B
Предишно отваряне	17.43
Предишно затваряне	12.6

Настроения в новините

By Acuity

50%

187 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

14.24 / 14.78 Подкрепа & съпротива

Hutchison China MediTech Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.05.2026 г., 23:41 ч. UTC

Печалби

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6.05.2026 г., 21:40 ч. UTC

Печалби

Nutrien Logs Higher Profit, Sales Growth in 1Q

6.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6.05.2026 г., 23:12 ч. UTC

Печалби

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6.05.2026 г., 23:11 ч. UTC

Печалби

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6.05.2026 г., 23:07 ч. UTC

Печалби

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6.05.2026 г., 23:05 ч. UTC

Печалби

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6.05.2026 г., 23:04 ч. UTC

Печалби

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6.05.2026 г., 22:50 ч. UTC

Печалби

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6.05.2026 г., 22:25 ч. UTC

Пазарно говорене

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6.05.2026 г., 22:05 ч. UTC

Пазарно говорене

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6.05.2026 г., 21:58 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6.05.2026 г., 21:47 ч. UTC

Пазарно говорене

Печалби

Costco Posts 13% Sales Growth in April -- Market Talk

6.05.2026 г., 21:46 ч. UTC

Печалби

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6.05.2026 г., 21:40 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6.05.2026 г., 21:35 ч. UTC

Пазарно говорене

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6.05.2026 г., 21:32 ч. UTC

Горещи акции

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6.05.2026 г., 21:29 ч. UTC

Печалби

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Hutchison China MediTech Ltd ADR Прогноза

Ценова цел

By TipRanks

48.92% нагоре

12-месечна прогноза

Среден 20 USD 48.92%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Hutchison China MediTech Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Hutchison China MediTech Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

14.24 / 14.78Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

187 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.